Market Currents
Ariad Pharmaceuticals (ARIA) -1.7% AH after an FDA panel votes13-1 not to recommend Taltorvic, a...
-
Tuesday, March 20, 2012, 4:56 PM ETAriad Pharmaceuticals (ARIA) -1.7% AH after an FDA panel votes13-1 not to recommend Taltorvic, a sarcoma drug developed by Ariad and Merck (MRK). The panel concluded Taltorvic's short-term benefits fail to "outweigh the risks of adverse reactions and a lack of evidence of improved overall survival." A rival drug from GlaxoSmithKline (GSK) received a thumbs-up earlier today. (previously)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
